Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECT OF PRIOR RADIOPHARMACEUTICAL ADMINISTRATION ON SCHILLING TEST-PERFORMANCE - ANALYSIS AND RECOMMENDATIONS
Autore:
ZUCKIER LS; STABIN M; KRYNYCKYI BR; ZANZONICO P; BINKERT B;
Indirizzi:
YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NUCL MED,ULLMANN BLDG,RM 121,1300 MORRIS PK AVE BRONX NY 10460 OAK RIDGE INST SCI & EDUC,RADIAT INTERNAL DOSE INFORMAT CTR OAK RIDGETN 00000 CORNELL UNIV,MED CTR,NEW YORK HOSP,DEPT RADIOL NEW YORK NY 10021
Titolo Testata:
The Journal of nuclear medicine
fascicolo: 12, volume: 37, anno: 1996,
pagine: 1995 - 1999
SICI:
0161-5505(1996)37:12<1995:EOPRAO>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
VITAMIN-B12 ABSORPTION TEST;
Keywords:
SCHILLING TEST; RADIOPHARMACEUTICALS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
17
Recensione:
Indirizzi per estratti:
Citazione:
L.S. Zuckier et al., "EFFECT OF PRIOR RADIOPHARMACEUTICAL ADMINISTRATION ON SCHILLING TEST-PERFORMANCE - ANALYSIS AND RECOMMENDATIONS", The Journal of nuclear medicine, 37(12), 1996, pp. 1995-1999

Abstract

Previously administered diagnostic and therapeutic radiopharmaceuticals may interfere with performance of the Schilling test for prolonged periods of time. Additionally, presence of confounding radionuclides in the urine may not be suspected if baseline urine measurements have not been performed before the examination. Methods: We assumed that a spurious contribution of counts corresponding to 1% of the administeredSchilling dose would begin to contribute clinically significant interference. Based on the typical amounts of radiopharmaceuticals administered, spectra of commonly used radionuclides and best available pharmacokinetic models of biodistribution and excretion, we estimated the interval required for 24-hr urinary excretion of diagnostic and therapeutic radiopharmaceuticals to drop below this threshold of significant interference. Results: For previously administered Tc-99m-based radiopharmaceuticals and I-123-NaI, the interval required for urinary levels of activity to fall below thresholds of allowable interference are between 2-5 days. For Ga-67-citrate, several In-111 compounds, I-131-MIBGand Tl-201-thallous chloride,periods of 12-44 days are estimated. Estimates for I-131-NaI vary greatly between 4 and 115 days, depending onthe amount administered, and the degree of thyroid uptake. Conclusion: Patients should be interviewed before performing the Schilling test to ensure that interfering radiopharmaceuticals have not been recentlyadministered. The estimates developed in this paper can serve as guidelines for the necessary waiting time between prior radiopharmaceutical administration and the Schilling examination.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/09/20 alle ore 06:25:35